Skip to main content
PMC home page
Biochemical Journal logoLink to Biochemical Journal
. 2002 Jun 1;364(Pt 2):507–515. doi: 10.1042/BJ20011373

The terminal six amino-acids of the carboxy cytoplasmic tail of CD36 contain a functional domain implicated in the binding and capture of oxidized low-density lipoprotein.

Eric Malaud 1, Delphine Hourton 1, Louise Marie Giroux 1, Ewa Ninio 1, Robin Buckland 1, John L McGregor 1
PMCID: PMC1222596  PMID: 12023894

Abstract

CD36, a major adhesion molecule expressed by monocytes/macrophages, plays a key role in the binding and internalization of oxidized low-density lipoprotein (OxLDL). This adhesion molecule, a member of an important scavenger receptor family, contains a very short C-terminal cytoplasmic tail that is known to induce intracellular signalling events. However, the domains on the cytoplasmic tail involved in such signal transduction are unknown. In this study, we have investigated the functional components of the cytoplasmic tail by site-directed mutagenesis coupled with functional OxLDL and monoclonal antibody (mAb) binding studies. Seven truncated or punctual CD36 constructs, localized in the cytoplasmic tail, were produced by site-directed mutagenesis. Each construct was stably expressed in HEK293 cells. We used a quantitative and a qualitative method, labelling OxLDL with either iodine or rhodamine, to determine the functional importance of the cytoplasmic domains in OxLDL internalization. Results indicate that: (1) a deletion of the last amino-acid (construct K472STOP) significantly reduces, compared with wild-type, the binding, internalization and degradation of OxLDL; (2) truncation of the last six amino-acids (construct R467STOP) significantly reduces OxLDL binding; (3) the above two constructs (K472STOP and R467STOP) showed a reduced rate of OxLDL internalization compared with wild-type; (4) the binding and rate of internalization of an anti-CD36 monoclonal antibody (10/5) was not affected by the above mentioned mutants (K472STOP and R467STOP), compared with wild-type. This study shows, for the first time, a specific site on the CD36 cytoplasmic tail that is critical for the binding, endocytosis and targeting of OxLDL.

Full Text

The Full Text of this article is available as a PDF (254.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abumrad N. A., el-Maghrabi M. R., Amri E. Z., Lopez E., Grimaldi P. A. Cloning of a rat adipocyte membrane protein implicated in binding or transport of long-chain fatty acids that is induced during preadipocyte differentiation. Homology with human CD36. J Biol Chem. 1993 Aug 25;268(24):17665–17668. [PubMed] [Google Scholar]
  2. Aiken M. L., Ginsberg M. H., Byers-Ward V., Plow E. F. Effects of OKM5, a monoclonal antibody to glycoprotein IV, on platelet aggregation and thrombospondin surface expression. Blood. 1990 Dec 15;76(12):2501–2509. [PubMed] [Google Scholar]
  3. Asch A. S., Barnwell J., Silverstein R. L., Nachman R. L. Isolation of the thrombospondin membrane receptor. J Clin Invest. 1987 Apr;79(4):1054–1061. doi: 10.1172/JCI112918. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Buege J. A., Aust S. D. Microsomal lipid peroxidation. Methods Enzymol. 1978;52:302–310. doi: 10.1016/s0076-6879(78)52032-6. [DOI] [PubMed] [Google Scholar]
  5. Bull H. A., Brickell P. M., Dowd P. M. Src-related protein tyrosine kinases are physically associated with the surface antigen CD36 in human dermal microvascular endothelial cells. FEBS Lett. 1994 Aug 29;351(1):41–44. doi: 10.1016/0014-5793(94)00814-0. [DOI] [PubMed] [Google Scholar]
  6. Daviet L., Craig A. G., McGregor L., Pinches R., Wild T. F., Berendt A. R., Newbold C. I., McGregor J. L. Characterization of two vaccinia CD36 recombinant-virus-generated monoclonal antibodies (10/5, 13/10): effects on malarial cytoadherence and platelet functions. Eur J Biochem. 1997 Jan 15;243(1-2):344–349. doi: 10.1111/j.1432-1033.1997.0344a.x. [DOI] [PubMed] [Google Scholar]
  7. Daviet L., Malvoisin E., Wild T. F., McGregor J. L. Thrombospondin induces dimerization of membrane-bound, but not soluble CD36. Thromb Haemost. 1997 Aug;78(2):897–901. [PubMed] [Google Scholar]
  8. Edelman P., Vinci G., Villeval J. L., Vainchenker W., Henri A., Miglierina R., Rouger P., Reviron J., Breton-Gorius J., Sureau C. A monoclonal antibody against an erythrocyte ontogenic antigen identifies fetal and adult erythroid progenitors. Blood. 1986 Jan;67(1):56–63. [PubMed] [Google Scholar]
  9. Endemann G., Stanton L. W., Madden K. S., Bryant C. M., White R. T., Protter A. A. CD36 is a receptor for oxidized low density lipoprotein. J Biol Chem. 1993 Jun 5;268(16):11811–11816. [PubMed] [Google Scholar]
  10. Febbraio M., Abumrad N. A., Hajjar D. P., Sharma K., Cheng W., Pearce S. F., Silverstein R. L. A null mutation in murine CD36 reveals an important role in fatty acid and lipoprotein metabolism. J Biol Chem. 1999 Jul 2;274(27):19055–19062. doi: 10.1074/jbc.274.27.19055. [DOI] [PubMed] [Google Scholar]
  11. Febbraio M., Podrez E. A., Smith J. D., Hajjar D. P., Hazen S. L., Hoff H. F., Sharma K., Silverstein R. L. Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice. J Clin Invest. 2000 Apr;105(8):1049–1056. doi: 10.1172/JCI9259. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Feng J., Han J., Pearce S. F., Silverstein R. L., Gotto A. M., Jr, Hajjar D. P., Nicholson A. C. Induction of CD36 expression by oxidized LDL and IL-4 by a common signaling pathway dependent on protein kinase C and PPAR-gamma. J Lipid Res. 2000 May;41(5):688–696. [PubMed] [Google Scholar]
  13. Gieseg S. P., Esterbauer H. Low density lipoprotein is saturable by pro-oxidant copper. FEBS Lett. 1994 May 2;343(3):188–194. doi: 10.1016/0014-5793(94)80553-9. [DOI] [PubMed] [Google Scholar]
  14. Greenlund A. C., Schreiber R. D., Goeddel D. V., Pennica D. Interferon-gamma induces receptor dimerization in solution and on cells. J Biol Chem. 1993 Aug 25;268(24):18103–18110. [PubMed] [Google Scholar]
  15. Greenwalt D. E., Scheck S. H., Rhinehart-Jones T. Heart CD36 expression is increased in murine models of diabetes and in mice fed a high fat diet. J Clin Invest. 1995 Sep;96(3):1382–1388. doi: 10.1172/JCI118173. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Greenwalt D. E., Watt K. W., So O. Y., Jiwani N. PAS IV, an integral membrane protein of mammary epithelial cells, is related to platelet and endothelial cell CD36 (GP IV). Biochemistry. 1990 Jul 31;29(30):7054–7059. doi: 10.1021/bi00482a015. [DOI] [PubMed] [Google Scholar]
  17. Huang M. M., Bolen J. B., Barnwell J. W., Shattil S. J., Brugge J. S. Membrane glycoprotein IV (CD36) is physically associated with the Fyn, Lyn, and Yes protein-tyrosine kinases in human platelets. Proc Natl Acad Sci U S A. 1991 Sep 1;88(17):7844–7848. doi: 10.1073/pnas.88.17.7844. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Huh H. Y., Pearce S. F., Yesner L. M., Schindler J. L., Silverstein R. L. Regulated expression of CD36 during monocyte-to-macrophage differentiation: potential role of CD36 in foam cell formation. Blood. 1996 Mar 1;87(5):2020–2028. [PubMed] [Google Scholar]
  19. Ibrahimi A., Sfeir Z., Magharaie H., Amri E. Z., Grimaldi P., Abumrad N. A. Expression of the CD36 homolog (FAT) in fibroblast cells: effects on fatty acid transport. Proc Natl Acad Sci U S A. 1996 Apr 2;93(7):2646–2651. doi: 10.1073/pnas.93.7.2646. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Janabi M., Yamashita S., Hirano K., Sakai N., Hiraoka H., Matsumoto K., Zhang Z., Nozaki S., Matsuzawa Y. Oxidized LDL-induced NF-kappa B activation and subsequent expression of proinflammatory genes are defective in monocyte-derived macrophages from CD36-deficient patients. Arterioscler Thromb Vasc Biol. 2000 Aug;20(8):1953–1960. doi: 10.1161/01.atv.20.8.1953. [DOI] [PubMed] [Google Scholar]
  21. Knowles D. M., 2nd, Tolidjian B., Marboe C., D'Agati V., Grimes M., Chess L. Monoclonal anti-human monocyte antibodies OKM1 and OKM5 possess distinctive tissue distributions including differential reactivity with vascular endothelium. J Immunol. 1984 May;132(5):2170–2173. [PubMed] [Google Scholar]
  22. Kunkel T. A., Roberts J. D., Zakour R. A. Rapid and efficient site-specific mutagenesis without phenotypic selection. Methods Enzymol. 1987;154:367–382. doi: 10.1016/0076-6879(87)54085-x. [DOI] [PubMed] [Google Scholar]
  23. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  24. Lipsky R. H., Eckert D. M., Tang Y., Ockenhouse C. F. The carboxyl-terminal cytoplasmic domain of CD36 is required for oxidized low-density lipoprotein modulation of NF-kappaB activity by tumor necrosis factor-alpha. Recept Signal Transduct. 1997;7(1):1–11. [PubMed] [Google Scholar]
  25. McClelland A., deBear J., Yost S. C., Meyer A. M., Marlor C. W., Greve J. M. Identification of monoclonal antibody epitopes and critical residues for rhinovirus binding in domain 1 of intercellular adhesion molecule 1. Proc Natl Acad Sci U S A. 1991 Sep 15;88(18):7993–7997. doi: 10.1073/pnas.88.18.7993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. McGilvray I. D., Serghides L., Kapus A., Rotstein O. D., Kain K. C. Nonopsonic monocyte/macrophage phagocytosis of Plasmodium falciparum-parasitized erythrocytes: a role for CD36 in malarial clearance. Blood. 2000 Nov 1;96(9):3231–3240. [PubMed] [Google Scholar]
  27. McGregor J. L., Catimel B., Parmentier S., Clezardin P., Dechavanne M., Leung L. L. Rapid purification and partial characterization of human platelet glycoprotein IIIb. Interaction with thrombospondin and its role in platelet aggregation. J Biol Chem. 1989 Jan 5;264(1):501–506. [PubMed] [Google Scholar]
  28. Nagy L., Tontonoz P., Alvarez J. G., Chen H., Evans R. M. Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma. Cell. 1998 Apr 17;93(2):229–240. doi: 10.1016/s0092-8674(00)81574-3. [DOI] [PubMed] [Google Scholar]
  29. Nakagawa T., Nozaki S., Nishida M., Yakub J. M., Tomiyama Y., Nakata A., Matsumoto K., Funahashi T., Kameda-Takemura K., Kurata Y. Oxidized LDL increases and interferon-gamma decreases expression of CD36 in human monocyte-derived macrophages. Arterioscler Thromb Vasc Biol. 1998 Aug;18(8):1350–1357. doi: 10.1161/01.atv.18.8.1350. [DOI] [PubMed] [Google Scholar]
  30. Nakata A., Nakagawa Y., Nishida M., Nozaki S., Miyagawa J., Nakagawa T., Tamura R., Matsumoto K., Kameda-Takemura K., Yamashita S. CD36, a novel receptor for oxidized low-density lipoproteins, is highly expressed on lipid-laden macrophages in human atherosclerotic aorta. Arterioscler Thromb Vasc Biol. 1999 May;19(5):1333–1339. doi: 10.1161/01.atv.19.5.1333. [DOI] [PubMed] [Google Scholar]
  31. Navazo M. D., Daviet L., Savill J., Ren Y., Leung L. L., McGregor J. L. Identification of a domain (155-183) on CD36 implicated in the phagocytosis of apoptotic neutrophils. J Biol Chem. 1996 Jun 28;271(26):15381–15385. doi: 10.1074/jbc.271.26.15381. [DOI] [PubMed] [Google Scholar]
  32. Nicholson A. C., Frieda S., Pearce A., Silverstein R. L. Oxidized LDL binds to CD36 on human monocyte-derived macrophages and transfected cell lines. Evidence implicating the lipid moiety of the lipoprotein as the binding site. Arterioscler Thromb Vasc Biol. 1995 Feb;15(2):269–275. doi: 10.1161/01.atv.15.2.269. [DOI] [PubMed] [Google Scholar]
  33. Ockenhouse C. F., Magowan C., Chulay J. D. Activation of monocytes and platelets by monoclonal antibodies or malaria-infected erythrocytes binding to the CD36 surface receptor in vitro. J Clin Invest. 1989 Aug;84(2):468–475. doi: 10.1172/JCI114188. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Oquendo P., Hundt E., Lawler J., Seed B. CD36 directly mediates cytoadherence of Plasmodium falciparum parasitized erythrocytes. Cell. 1989 Jul 14;58(1):95–101. doi: 10.1016/0092-8674(89)90406-6. [DOI] [PubMed] [Google Scholar]
  35. Pearce S. F., Roy P., Nicholson A. C., Hajjar D. P., Febbraio M., Silverstein R. L. Recombinant glutathione S-transferase/CD36 fusion proteins define an oxidized low density lipoprotein-binding domain. J Biol Chem. 1998 Dec 25;273(52):34875–34881. doi: 10.1074/jbc.273.52.34875. [DOI] [PubMed] [Google Scholar]
  36. Pearce S. F., Wu J., Silverstein R. L. A carboxyl terminal truncation mutant of CD36 is secreted and binds thrombospondin: evidence for a single transmembrane domain. Blood. 1994 Jul 15;84(2):384–389. [PubMed] [Google Scholar]
  37. Pennica D., Lam V. T., Weber R. F., Kohr W. J., Basa L. J., Spellman M. W., Ashkenazi A., Shire S. J., Goeddel D. V. Biochemical characterization of the extracellular domain of the 75-kilodalton tumor necrosis factor receptor. Biochemistry. 1993 Mar 30;32(12):3131–3138. doi: 10.1021/bi00063a027. [DOI] [PubMed] [Google Scholar]
  38. Puente Navazo M. D., Daviet L., Ninio E., McGregor J. L. Identification on human CD36 of a domain (155-183) implicated in binding oxidized low-density lipoproteins (Ox-LDL). Arterioscler Thromb Vasc Biol. 1996 Aug;16(8):1033–1039. doi: 10.1161/01.atv.16.8.1033. [DOI] [PubMed] [Google Scholar]
  39. Rasmussen J. T., Berglund L., Rasmussen M. S., Petersen T. E. Assignment of disulfide bridges in bovine CD36. Eur J Biochem. 1998 Oct 15;257(2):488–494. doi: 10.1046/j.1432-1327.1998.2570488.x. [DOI] [PubMed] [Google Scholar]
  40. Ren Y., Silverstein R. L., Allen J., Savill J. CD36 gene transfer confers capacity for phagocytosis of cells undergoing apoptosis. J Exp Med. 1995 May 1;181(5):1857–1862. doi: 10.1084/jem.181.5.1857. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Savill J., Hogg N., Ren Y., Haslett C. Thrombospondin cooperates with CD36 and the vitronectin receptor in macrophage recognition of neutrophils undergoing apoptosis. J Clin Invest. 1992 Oct;90(4):1513–1522. doi: 10.1172/JCI116019. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Schüepp B. J., Pfister H., Clemetson K. J., Silverstein R. L., Jungi T. W. CD36-mediated signal transduction in human monocytes by anti-CD36 antibodies but not by anti-thrombospondin antibodies recognizing cell membrane-bound thrombospondin. Biochem Biophys Res Commun. 1991 Feb 28;175(1):263–270. doi: 10.1016/s0006-291x(05)81229-x. [DOI] [PubMed] [Google Scholar]
  43. Setiadi H., Disdier M., Green S. A., Canfield W. M., McEver R. P. Residues throughout the cytoplasmic domain affect the internalization efficiency of P-selectin. J Biol Chem. 1995 Nov 10;270(45):26818–26826. doi: 10.1074/jbc.270.45.26818. [DOI] [PubMed] [Google Scholar]
  44. Silverstein R. L., Asch A. S., Nachman R. L. Glycoprotein IV mediates thrombospondin-dependent platelet-monocyte and platelet-U937 cell adhesion. J Clin Invest. 1989 Aug;84(2):546–552. doi: 10.1172/JCI114197. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Stanton L. W., White R. T., Bryant C. M., Protter A. A., Endemann G. A macrophage Fc receptor for IgG is also a receptor for oxidized low density lipoprotein. J Biol Chem. 1992 Nov 5;267(31):22446–22451. [PubMed] [Google Scholar]
  46. Talle M. A., Rao P. E., Westberg E., Allegar N., Makowski M., Mittler R. S., Goldstein G. Patterns of antigenic expression on human monocytes as defined by monoclonal antibodies. Cell Immunol. 1983 May;78(1):83–99. doi: 10.1016/0008-8749(83)90262-9. [DOI] [PubMed] [Google Scholar]
  47. Tandon N. N., Kralisz U., Jamieson G. A. Identification of glycoprotein IV (CD36) as a primary receptor for platelet-collagen adhesion. J Biol Chem. 1989 May 5;264(13):7576–7583. [PubMed] [Google Scholar]
  48. Tao N., Wagner S. J., Lublin D. M. CD36 is palmitoylated on both N- and C-terminal cytoplasmic tails. J Biol Chem. 1996 Sep 13;271(37):22315–22320. doi: 10.1074/jbc.271.37.22315. [DOI] [PubMed] [Google Scholar]
  49. Tontonoz P., Nagy L., Alvarez J. G., Thomazy V. A., Evans R. M. PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell. 1998 Apr 17;93(2):241–252. doi: 10.1016/s0092-8674(00)81575-5. [DOI] [PubMed] [Google Scholar]
  50. el-Saadani M., Esterbauer H., el-Sayed M., Goher M., Nassar A. Y., Jürgens G. A spectrophotometric assay for lipid peroxides in serum lipoproteins using a commercially available reagent. J Lipid Res. 1989 Apr;30(4):627–630. [PubMed] [Google Scholar]

Articles from Biochemical Journal are provided here courtesy of The Biochemical Society

RESOURCES